Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, explained how results from the phase 3 trial could change the treatment opportunities for patients with aRCC, as well as the treatment landscape more broadly.
The investigative therapy targets a specific molecule that is generally only expressed on the prostate cancer cell, according to a recent interview.
Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses some of the adverse events patients experienced during the phase 3 trial assessing lutetium Lu 177 dotatate for midgut neuroendocrine tumors.
Medical oncologist Michael Morris, MD, discussed the newest findings of the phase 3 VISION trial, which is investigating the use of 177Lu-PSMA-617 in patients with advanced prostate cancer.
Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses the methods used during the phase 3 trial to assess lutetium Lu 177 dotatate for midgut neuroendocrine tumors.
Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, explained what patients with aRCC who were given either nivolumab plus cabozantinib or sunitinib reported in regard to their quality of life during treatment.
Notably, the investigative treatment avoids many of the severe adverse effects common in traditional therapies.
Warren O, a person living with HIV for 11 years who has first-hand experience with HIV stigma, discusses his perspective on how the reduction of stigma could help to end the HIV epidemic.
The use of 177Lu-PSMA-617 resulted in a 60% reduction in radiographic progression or death among patients with advanced prostate cancer.
Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses the efficacy and safety of lutetium Lu 177 dotatate for midgut neuroendocrine tumors.
Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, gives an overview of the phase 3 trial assessing lutetium Lu 177 dotatate for midgut neuroendocrine tumors.
New research presented at the American Society of Clinical Oncology 2021 annual meeting has found encouraging results with the use of 177Lu-PSMA-617 in patients with advanced prostate cancer.
Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, detailed some of the AEs experienced by patients with aRCC who were given either nivolumab plus cabozantinib or sunitinib.
Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, explained how the phase 3 CheckMate 9ER trial was conducted in order to assess the outcomes by baseline disease characteristics for patients with aRCC.
Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, discusses her presentation on nivolumab plus cabozantinib versus sunitinib for aRCC.
Semaglutide (Ozempic) is a glucagon-like peptide 1 receptor agonist, approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Pharmacy Times spoke with Tomas Villanueva, DO, MBA, FACPE, SFHM, practicing health care provider, and associate vice president for clinical resources at Vizient, about what pharmacists should know about vaccine hesitancy in general.
Catherine Duggan, FRPharmS, CEO of International Pharmaceutical Federation, discusses the role and the authorities of the pharmacist internationally, and the effect the pandemic has had on that role globally.
Although many health systems offer wellness program for their staff, awareness and utilization of these services remains low.
Not only are pharmacists drug experts, but the pandemic demonstrated that they can also perform COVID-19 testing and vaccinations alongside physicians and other health care providers.
Pharmacy Times spoke with Tomas Villanueva, DO, MBA, FACPE, SFHM, practicing health care provider, and associate vice president for clinical resources at Vizient, about the value of the pharmacist in addressing vaccine hesitancy.
In March, the FDA approved dasiglucagon (Zegalogue) for the treatment of severe hypoglycemia in people with diabetes aged 6 years or older.
Pharmacy Times spoke with Dr. Mark Pollack, MD, about Mental Health Awareness Month and the latest information on depression/medication adherence.
Pharmacy Times spoke with Tomas Villanueva, DO, MBA, FACPE, SFHM, practicing health care provider, and associate vice president for clinical resources at Vizient, about how hospitals are tailoring their approaches to vaccine hesitancy to address social detriments.
Lynlee Burton, head of the Center for Vaccines and Emerging Infectious Diseases at PRA Health Sciences, discusses how the pandemic has impacted the way the United States views the pharmacist within the immunization space.
Jay Lieberman, MD, a pediatric infectious disease specialist and the senior medical director of PRA Health Sciences, discusses how health care professionals should approach discussing issues around vaccine hesitancy with parents.
Susan Lang, CEO of XIL Health and former senior executive at Express Scripts, discusses some of the reimbursement issues that have been arising for pharmacies while administering COVID-19 vaccines.
Pharmacy Times spoke with Tomas Villanueva, DO, MBA, FACPE, SFHM, practicing health care provider, and associate vice president for clinical resources at Vizient, about specific initiatives for health systems and how to help mitigate vaccine hesitancy.
Lynlee Burton, head of the Center for Vaccines and Emerging Infectious Diseases at PRA Health Sciences, discusses the significance of short vaccine development timelines on the future development of COVID-19 vaccines.
Jay Lieberman, MD, a pediatric infectious disease specialist and the senior medical director of PRA Health Sciences, discusses his decision to enroll his twin daughters in the Moderna COVID-19 vaccine trial.
